Targets › AVPR2
8 programs from 7 companies in 21 trials: 9 Phase 3, 5 Phase 4, 4 Phase 1, 3 Phase 2; Metabolic and endocrine, Genitourinary, Gastroenterology; next expected readout Jan 2027.
G protein-coupled receptor for arginine vasopressin, an antidiuretic that promotes renal water reabsorption. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of downstream effectors, such as adenylate cyclase (cAMP). (UniProt, P30518)
Open in Phaseline: the race on AVPR2, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Tiohundra | Vasopressin Vasopressin receptor agonist | AVPR2, AVPR1A, AVPR1B | Phase 3 | Cardiac Arrest;In-hospital Cardiac Arrest; Methylprednisolone; Vasopressin; Adrenaline; Randomized Clinical Trial; Vasoplegic Syndrome of Cardiac Surgery; Retained Products of Conception; Shock … | Jan 2027 |
| Hamilton Health Sciences Corporation | Desmopressin Vasopressin receptor agonist | AVPR2, AVPR1A, AVPR1B | Phase 3 | Chronic Kidney Diseases | Feb 2027 |
| Assistance Publique - Hôpitaux de Paris | Desmopressin Acetate Vasopressin receptor agonist | AVPR2, AVPR1A, AVPR1B | Phase 3 | Hyponatremia | Dec 2027 |
| Otsuka | Tolvaptan (OPC-41061) Vasopressin V2 receptor antagonist | AVPR2 | Phase 3 | Autosomal Recessive Polycystic Kidney (ARPKD) | Dec 2028 |
| Medical University of Bialystok | Desmopressin Vasopressin receptor agonist | AVPR2, AVPR1A, AVPR1B | Phase 3 | Kidney Biopsy | – |
| National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Desmopressin Vasopressin receptor agonist | AVPR2, AVPR1A, AVPR1B | Phase 2 | Cushing Syndrome | Oct 2028 |
| Otsuka | NDI-5001 Vasopressin V2 receptor agonist | AVPR2 | Phase 1 | Diabetes Insipidus | Aug 2027 |
| PharmaIN | Terlipressin (PHIN-214) Vasopressin V1 receptor binding agent; Vasopressin V2 receptor binding agent | AVPR1A, AVPR1B, AVPR2 | Phase 1 | Cirrhosis, Liver | – |
Sepsis (2) Septic Shock (2) Hyponatremia (1) Kidney Biopsy (1) Cushing Syndrome (1) Chronic Kidney Diseases (1) Diabetes Insipidus (1) Cirrhosis, Liver (1) Autosomal Recessive Polycystic Kidney (ARPKD) (1) Cardiac Arrest;In-hospital Cardiac Arrest; Methylprednisolone; Vasopressin; Adrenaline; Randomized Clinical Trial (1) Vasoplegic Syndrome of Cardiac Surgery (1) Retained Products of Conception (1)
small molecule (8)
Otsuka (2) Assistance Publique - Hôpitaux de Paris (1) Medical University of Bialystok (1) National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (1) Hamilton Health Sciences Corporation (1) PharmaIN (1) Tiohundra (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.